CROOKE R M: "Antisense oligonucleotides as therapeutics for hyperlipidaemias", EXPERT OPINION ON BIOLOGICAL THERAPY,, vol. 5, no. 7, 1 July 2005 (2005-07-01), pages 907-917, XP009075941, ISSN: 1471-2598, DOI: 10.1517/14712598.5.7.907 (B1)

DE GROOTH ET AL.: 'A review of CETP and its relation to atherosclerosis.' J. LIPID RES. vol. 45, no. 11, November 2004, pages 1967 - 1974, XP055135945 (B1)

FAHIE-WILSON M ET AL: "HDL cholesterol and the acute phase reaction following myocardial infarction and acute pancreatitis", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 167, no. 2, 14 August 1987 (1987-08-14), pages 197-209, XP023397692, ISSN: 0009-8981, DOI: 10.1016/0009-8981(87)90372-X [retrieved on 1987-08-14] (B1)

GRAHAM MARK J ET AL: "Antisense Inhibition of ApoC-III in Rhesus Monkeys Reduces Plasma Triglycerides and Raises HDL-C Without Increasing Hepatic Fat", CIRCULATION RESEARCH, vol. 109, no. 12, December 2011 (2011-12), page E60, XP009180729, & AMERICAN-HEART-ASSOCIATION SCIENTIFIC SESSIONS ON RESUSCITATION SCIENCE SYMPOSIUM; ORLANDO, FL, USA; NOVEMBER 12 -16, 2011 (B1)

HERNANDEZ ET AL.: 'Regulation of hepatic ApoC3 expression by PGC-1 beta mediates hypolipidemic effect of nicotinic acid.' CELL. METAB. vol. 12, no. 4, 06 October 2010, pages 411 - 419, XP055135947 (B1)

M. J. GRAHAM ET AL: "Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans", CIRCULATION RESEARCH, vol. 112, no. 11, 29 March 2013 (2013-03-29), pages 1479-1490, XP055146075, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.111.300367 (B1)

YUAN ET AL.: 'Hypertriglyceridemia: its etiology, effects and treatment.' CMAJ. vol. 176, no. 8, 10 April 2007, pages 1113 - 1120, XP055135946 (B1)

MULLICK ADAM E ET AL: "Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.", May 2011 (2011-05), JOURNAL OF LIPID RESEARCH MAY 2011, VOL. 52, NR. 5, PAGE(S) 885 - 896, XP002731099, ISSN: 0022-2275 * abstract * (B1)

POLLIN TONI I ET AL: "A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.", 12 December 2008 (2008-12-12), SCIENCE (NEW YORK, N.Y.) 12 DEC 2008, VOL. 322, NR. 5908, PAGE(S) 1702 - 1705, XP002731095, ISSN: 1095-9203 * abstract * (B1)

SUBRAMANIAM AMUTHAKANNAN ET AL: "ApoC-III antisense Oligonucleotides reduce liver mRNA and serum triglyceride levels in hypertriglyceridemic rats", DIABETES; 65TH ANNUAL MEETING OF THE AMERICAN-DIABETES-ASSOCIATION, AMERICAN DIABETES ASSOCIATION, US; SAN DIEGO, CA, USA , vol. 54, no. Suppl. 1 1 January 2005 (2005-01-01), page 1, XP008161449, ISSN: 0012-1797 Retrieved from the Internet: URL:http://diabetes.diabetesjournals.org/ [retrieved on 2014-10-14] (B1)

US-A1- 2004 224 304 (B1)

US-A1- 2006 264 395 (B1)

WO-A1-2010/107838 (B1)

MAEDA NOBUYO ET AL: "Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269, no. 38, 23 September 1994 (1994-09-23), pages 23610-23616, XP002508088, ISSN: 0021-9258 (B1)